The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Abstract
Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated patients with relapsed/refractory AML by promoting leukemic cell differentiation. Here, we studied the clonal basis of response and acquired resistance to enasidenib treatment. Using sequential patient samples, we determined the clonal structure of hematopoietic cell populations at different stages of differentiation. Before therapy, IDH2-mutant clones showed variable differentiation arrest. Enasidenib treatment promoted hematopoietic differentiation from either terminal or ancestral mutant clones; less frequently, treatment promoted differentiation of nonmutant cells. Analysis of paired diagnosis/relapse samples did not identify second-site mutations in IDH2 at relapse. Instead, relapse arose by clonal evolution or selection of terminal or ancestral clones, thus highlighting multiple bypass pathways that could potentially be targeted to restore differentiation arrest. These results show how mapping of clonal structure in cell populations at different stages of differentiation can reveal the response and evolution of clones during treatment response and relapse. Mapping of the clonal structure of bone marrow cells in patients with acute myeloid leukemia treated with the IDH2 inhibitor enasidenib reveals heterogeneity in the cellular differentiation response and in mechanisms of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, it is universal in single-cell genotyping to observe a distribution of scVAFs that will range from ∼1% (0.01) to ∼99% (0.99).59,99,112”
From Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging (2024) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Self-citationGrimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationIdentification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Analysis and design of RNA sequencing experiments for identifying isoform regulation
Katz, Y., Wang, E. T., Airoldi, E. M., & Burge, C. B. (2010) · Nature Methods · doi:10.1038/nmeth.1528 · Cited by 1,353
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads
Lunter, G., & Goodson, M. (2011) · Genome Research · doi:10.1101/gr.111120.110 · Cited by 1,016
The DEAD-box protein family of RNA helicases
Cordin, O., Banroques, J., Tanner, N. K., & Linder, P. (2005) · Gene · doi:10.1016/j.gene.2005.10.019 · Cited by 993
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Self-citationPaschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004315 · Cited by 721
Self-citationCorces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324297111 · Cited by 705
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Goardon, N., Marchi, E., Atzberger, A., Quek, L. S., Schuh, A., Soneji, S., Woll, P. S., Mead, A. J., Alford, K. A., Rout, R., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.012 · Cited by 682
Self-citationEpigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
Kulis, M., Heath, S., Bibikova, M., Queirós, A. C., Navarro, A., Clot, G., Martínez-Trillos, A., Castellano, G., Brun-Heath, I., Pinyol, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2443 · Cited by 578
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., Bottomly, D., Wilmot, B., McWeeney, S. K., Tognon, C. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214514 · Cited by 571
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1034 · Cited by 471
Self-citationGaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 463
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F., Patel, J. L., Dillon, R. J., Vijay, P., Brown, A. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4125 · Cited by 402
Self-citationEnasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L., Shih, A., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O. A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 359
Self-citationBCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation
Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., et al. (2017) · Nature · doi:10.1038/nature24294 · Cited by 354
Divergent clonal selection dominates medulloblastoma at recurrence
Morrissy, A. S., Garzia, L., Shih, D. J. H., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F. M. G., Ramaswamy, V., Lindsay, P. E., et al. (2016) · Nature · doi:10.1038/nature16478 · Cited by 334
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
He, J., Abdel-Wahab, O. I., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J. L., Krivstov, A. V., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 309
Self-citationThe genomic landscape of core-binding factor acute myeloid leukemias
Faber, Z. J., Chen, X. '., Gedman, A. L., Boggs, K., Cheng, J., Ma, J., Radtke, I., Chao, J.-R., Walsh, M. P., Song, G., et al. (2016) · Nature Genetics · doi:10.1038/ng.3709 · Cited by 278
Heidel, F., Solem, F. K., Breitenbuecher, F., Lipka, D. B., Kasper, S., Thiede, M. H., Brandts, C., Serve, H., Roesel, J., Giles, F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2469 · Cited by 270
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Green, C. L., Evans, C. M., Zhao, L., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2011) · Blood · doi:10.1182/blood-2010-12-322479 · Cited by 268
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells
Karamitros, D., Stoilova, B., Aboukhalil, Z., Hamey, F., Reinisch, A., Samitsch, M., Quek, L., Otto, G., Repapi, E., Doondeea, J., et al. (2018) · Nature Immunology · doi:10.1038/s41590-017-0001-2 · Cited by 263
Self-citationPrp43: An RNA helicase-like factor involved in spliceosome disassembly
Arenas, J. E., & Abelson, J. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.11798 · Cited by 253
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K. S., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.016 · Cited by 201
Self-citationPrediction of Resistance to Small Molecule FLT3 Inhibitors
Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 181
Farrar, J. E., Schuback, H. L., Ries, R. E., Wai, D., Hampton, O. A., Treviño, L. R., Alonzo, T. A., Auvil, J. M. G., Davidsen, T. M., Gesuwan, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1015 · Cited by 168
Quek, L. S., Otto, G., Garnett, C., Lhermitte, L., Karamitros, D., Stoilova, B., Lau, I., Doondeea, J. B., Usukhbayar, B., Kennedy, A., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151775 · Cited by 161
Self-citationAge-related mutations and chronic myelomonocytic leukemia
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., Pomicter, A. D., Reynolds, K. R., Eiring, A. M., Kronenberg, Z. N., et al. (2015) · Leukemia · doi:10.1038/leu.2015.337 · Cited by 140
Shih, A. H., Meydan, C., SHANK, K. R., Garrett-Bakelman, F. E., Ward, P. S., Intlekofer, A. M., Nazir, A., Stein, E. M., Knapp, K. M., Glass, J. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1049 · Cited by 116
Self-citationFourmann, J., Schmitzová, J., Christian, H., Urlaub, H., Ficner, R., Boon, K.-L., Fabrizio, P., & Lührmann, R. (2013) · Genes & Development · doi:10.1101/gad.207779.112 · Cited by 109
Single-cell mutational profiling and clonal phylogeny in cancer
Potter, N. E., Ermini, L., Papaemmanuil, E., Cazzaniga, G., Vijayaraghavan, G., Titley, I., Ford, A., Campbell, P., Kearney, L., & Greaves, M. (2013) · Genome Research · doi:10.1101/gr.159913.113 · Cited by 107
Fasan, A., Eder, C., Haferlach, C., Großmann, V., Kohlmann, A., Dicker, F., Kern, W., Haferlach, T., & Schnittger, S. (2012) · Leukemia · doi:10.1038/leu.2012.174 · Cited by 102
Structural insights into the mechanism of the DEAH-box RNA helicase Prp43
Tauchert, M. J., Fourmann, J., Lührmann, R., & Ficner, R. (2017) · eLife · doi:10.7554/elife.21510 · Cited by 101
Craddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88
Self-citationSomatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia
Li, M., Collins, R., Jiao, Y., Ouillette, P. D., Bixby, D. L., Erba, H. P., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Malek, S. N. (2011) · Blood · doi:10.1182/blood-2011-05-356204 · Cited by 71
Murakami, K., Nakano, K., Shimizu, T., & Ohto, U. (2017) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x17007336 · Cited by 46
Cited by
McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Morita, K., Wang, F., Jahn, K., Hu, T., Tanaka, T., Sasaki, Y., Kuipers, J., Loghavi, S., Wang, S. A., Yan, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19119-8 · Cited by 383
Jakobsen, N. A., Turkalj, S., Zeng, A. G. X., Stoilova, B., Metzner, M., Rahmig, S., Nagree, M. S., Shah, S., Moore, R., Usukhbayar, B., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.05.010 · Cited by 130
Self-citationSepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Clonal hematopoiesis and risk for hematologic malignancy
Warren, J. T., & Link, D. C. (2020) · Blood · doi:10.1182/blood.2019000991 · Cited by 28
Metadata
- Authors
- Quek, L., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M., Shih, A., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., Saada, V., Alsafadi, S., Vijayabaskar, M. S., Peniket, A., Bernard, O. A., Agresta, S., Yen, K., MacBeth, K., Stein, E., Vassiliou, G. S., Levine, R., De Botton, S., Thakurta, A., Penard-Lacronique, V., & Vyas, P.
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-07-16
- Volume
- 24
- Issue
- 8
- Pages
- 1167-1177
- ISSN
- 1078-8956
- 1546-170X
- PMC
- PMC6925974
- Cited by
- 200
- References
- 56
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
